文献速递肿瘤 PET/CT

18F-DCFPyL PET/CT在前列腺癌初诊盆腔淋巴结分期中的诊断准确性:SALT试验

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-08-12

SALT trial为前瞻性多中心队列研究,纳入117例初诊前列腺癌患者,在机器人辅助根治性前列腺切除加扩大盆腔淋巴结清扫前行18F-DCFPyL PET/CT,以术后病理为金标准。患者层面检出盆腔淋巴结转移的灵敏度41.2%、特异度94.0%、阳性预测值53.8%、阴性预测值90.4%,作者认为当前PSMA PET/CT不能替代诊断性ePLND。

要点

  • 18F-DCFPyL PET/CT对初诊前列腺癌盆腔淋巴结转移特异度高(94.0%),灵敏度有限(41.2%)。
  • 阴性预测值90.4%,但阳性预测值仅53.8%,阳性结果需病理确认。
  • 研究结论认为当前PSMA PET/CT成像不能替代诊断性扩大盆腔淋巴结清扫。

核心结论

  • 18F-DCFPyL PET/CT对初诊前列腺癌盆腔淋巴结转移检出特异度高而灵敏度有限,目前不能替代诊断性ePLND。

研究设计与样本

  • 患者在接受机器人辅助根治性前列腺切除加扩大盆腔淋巴结清扫前行18F-DCFPyL PET/CT,图像由两名经验丰富的核医学医师审阅并与术后病理对照。
  • 共分析117例患者,淋巴结局灶转移(N1)经组织学诊断17/117例(14.5%)。

主要发现

  • 患者层面18F-DCFPyL PET/CT检出盆腔淋巴结转移的灵敏度为41.2%(CI 19.4-66.5%)。
  • 特异度为94.0%(CI 86.9-97.5%),阳性预测值为53.8%(CI 26.1-79.6%),阴性预测值为90.4%(CI 82.6-95.0%)。

临床怎么用

  • 初诊前列腺癌分期中,18F-DCFPyL PET/CT高特异度支持其阳性结果具有较高置信度,但灵敏度有限。
  • 阴性18F-DCFPyL PET/CT不能排除盆腔淋巴结转移,当前成像不能替代诊断性ePLND。
  • PSMA PET/CT在初诊前列腺癌分期中的确切地位仍需进一步研究确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The detection of lymph-node metastases (N1) with conventional imaging such as magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for primarily diagnosed prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) PET/CT is successfully introduced for the staging of (biochemically) recurrent PCa. Besides the frequently used 68gallium-labelled PSMA tracers, 18fluorine-labelled PSMA tracers are available. This study examined the diagnostic accuracy of 18F-DCFPyL (PSMA) PET/CT for lymph-node staging in primary PCa. METHODS: This was a prospective, multicentre cohort study. Patients with primary PCa underwent 18F-DCFPyL PET/CT prior to robot-assisted radical prostatectomy (RARP) with extended pelvic lymph-node dissection (ePLND). Patients were included between October 2017 and January 2020. A Memorial Sloan Kettering Cancer Centre (MSKCC) nomogram risk probability of ≥ 8% of lymph-node metastases was set to perform ePLND. All images were reviewed by two experienced nuclear physicians, and were compared with post-operative histopathologic results. RESULTS: A total of 117 patients was analysed. Lymph-node metastases (N1) were histologically diagnosed in 17/117 patients (14.5%). The sensitivity, specificity, positive predictive value and negative predictive value for the 18F-DCFPyL PET/CT detection of pelvic lymph-node metastases on a patient level were 41.2% (confidence interval (CI): 19.4-66.5%), 94.0% (CI 86.9-97.5%), 53.8% (CI 26.1-79.6%) and 90.4% (CI 82.6-95.0%), respectively. CONCLUSION: 18F-DCFPyL PET/CT showed a high specificity (94.4%), yet a limited sensitivity (41.2%) for the detection of pelvic lymph-node metastases in primary PCa. This implies that current PSMA PET/CT imaging cannot replace diagnostic ePLND. Further research is necessary to define the exact place of PSMA PET/CT imaging in the primary staging of PCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jansen BHE, Bodar YJL, Zwezerijnen GJC, et al. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Eur J Nucl Med Mol Imaging. 2020. PMID: 32789599. doi:10.1007/s00259-020-04974-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。